- Home
- AUTL vs AVTX Comparison
AUTL vs AVTX Comparison
Compare AUTL & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | AVTX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.6M | 328.4M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AUTL | AVTX |
|---|---|---|
| Price | $1.61 | $17.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $8.50 | ★ $40.57 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | $10,120,000.00 | ★ $27,813,137.00 |
| Revenue This Year | $80.32 | N/A |
| Revenue Next Year | $53.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 496.00 | ★ 2312.27 |
| 52 Week Low | $1.18 | $4.73 |
| 52 Week High | $2.70 | $24.27 |
Technical Indicators
Market Signals| Indicator | AUTL | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 64.69 |
| Support Level | $1.41 | $13.13 |
| Resistance Level | $1.73 | $19.06 |
| Average True Range (ATR) | 0.11 | 1.06 |
| MACD | 0.01 | 0.55 |
| Stochastic Oscillator | 81.67 | 92.22 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.